Bortezomib-induced peripheral neuropathy in patients with multiple myeloma.

Abstract

Bortezomib-induced peripheral neuropathy (BIPN) often is difficult to manage or reverse once it occurs. Treatment usually involves dose-reduction, interruption, or cessation of therapy, as no other interventions have been proven effective. Oncology nurses must be vigilant and recognize BIPN early to prevent patients from experiencing symptoms and… (More)
DOI: 10.1188/12.CJON.86-89

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.